Nail Involvement in Autoimmune Bullous Diseases
Nail involvement in autoimmune bullous diseases (AIBD) covers a range of nail unit changes that develop when autoantibodies attack the junctions between epidermal cells (desmosomes) or the anchoring structures between epidermis and dermis (hemidesmosomes) in the nail matrix, nail bed and nail folds.
Nail changes affect 15–30% of patients with pemphigus vulgaris (PV) and up to 40–50% of those with subepidermal blistering diseases such as epidermolysis bullosa acquisita (EBA) or mucous membrane pemphigoid (MMP).
- Blistering Within the Epidermis (Intraepidermal Blistering – Pemphigus Group):
- IgG autoantibodies against desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1) break the connections between keratinocytes (acantholysis).
- When acantholysis occurs in the nail folds and matrix, the epidermis separates into shallow, thin, fragile blisters, causing bullous paronychia and temporarily shutting down the matrix, which leads to shedding of the nail plate (onychomadesis).
- Blistering Beneath the Epidermis (Subepidermal Blistering – Pemphigoid Group and EBA):
- Autoantibodies against BP180/BP230 (in pemphigoid) or type VII collagen (in EBA) disrupt the basement membrane zone.
- Because the blister lies deep, below the basement membrane, the inflammation progresses to fibrosis and scarring. When this happens in the matrix, the nail-forming tissue is permanently destroyed, leading to pterygium and permanent nail loss (anonychia).
Nail changes in autoimmune blistering diseases often appear before or alongside a generalized flare of the underlying disease. Weeping bullous paronychia is easily misdiagnosed as a bacterial infection (staphylococci, Pseudomonas) or as Candida, leading to overuse of topical antibiotics or antifungals and delaying immunosuppressive treatment. At Haute-Derma, whenever we see blistering, eroded paronychia on several fingers, we perform direct immunofluorescence (DIF) of the periungual skin together with ELISA (anti-Dsg1, anti-Dsg3, anti-BP180) to confirm the diagnosis and start corticosteroids or rituximab without delay.
Clinical Features and Classification by Disease
- Bullous paronychia: The proximal and lateral nail folds become red and swollen, with very painful blisters containing clear fluid or sterile pus.
- Nail shedding (onychomadesis): The nail plate separates completely from its base (because the matrix is temporarily damaged by necrosis or acantholysis) and comes off, leaving a raw, red nail bed.
- Subungual hemorrhage / hematoma: Rupture of capillaries in the nail bed basement membrane forms dark red or black collections of blood under the nail plate.
- Matrix scarring and permanent nail loss (pterygium / anonychia): Common in EBA and MMP, because subepidermal blisters heal with fibrous scar tissue.
Patterns by Disease
- Pemphigus vulgaris (PV):
- Main features: painful paronychia, shallow fragile blisters, shedding of the nail plate on several fingers (onychomadesis) and splinter hemorrhages.
- Outlook: Permanent scarring is uncommon if the underlying disease is controlled.
- Bullous pemphigoid (BP):
- Main features: tense blisters, sometimes blood-filled, on the skin around the nails and on the palms and soles. The nail plate may become rippled or lift slightly.
- Epidermolysis bullosa acquisita (EBA) and MMP:
- Main features: blisters after minor trauma (skin fragility), blisters under the nail, rapidly progressive scarring, fusion of the proximal nail fold to the nail bed (pterygium) and complete nail loss (anonychia).
Treatment Protocol and Medical Care at Haute-Derma
Treating nail involvement in autoimmune blistering diseases goes hand in hand with controlling the underlying systemic disease. Local care plays a supporting role, preventing secondary infection and easing symptoms.
Local Wound Care and Repair
- Managing blisters around the nail: Do not remove the blister roof. Drain the fluid with a sterile needle to relieve painful pressure, leaving the roof in place as a natural biological dressing.
- Preventing secondary infection: Soaks or compresses with a mild antiseptic (chlorhexidine 0.05% or povidone-iodine 1%) for 10–15 minutes a day.
- Reducing local inflammation: clobetasol propionate 0.05% ointment or tacrolimus 0.1% ointment applied around the nail folds to calm local acantholysis.
Systemic Immunomodulatory Therapy
- Systemic corticosteroids (initial treatment):
- Prednisolone 0.5–1.0 mg/kg/day by mouth to bring acute flares under control quickly.
- Rituximab (anti-CD20 monoclonal antibody, the gold standard):
- Indication: First-line therapy for moderate to severe pemphigus vulgaris and for treatment-resistant blistering diseases.
- Regimen: 1000 mg IV on day 1 and day 15 (or 375 mg/m² weekly for 4 weeks).
- Effect: Shuts down production of pathogenic IgG autoantibodies, allowing the paronychia to heal and a new nail plate to grow within 12–16 weeks.
- High-Dose Intravenous Immunoglobulin (IVIG) and Conventional Immunosuppressants:
- IVIG: 2 g/kg per 4-week cycle for severe, treatment-resistant cases or when corticosteroids or rituximab are contraindicated.
- Mycophenolate mofetil (MMF): 2–3 g/day, or azathioprine: 1.5–2.5 mg/kg/day, used as maintenance to reduce the steroid dose (steroid-sparing agents).
